Measurement of involuntary muscle contraction in adults with spasticity

Not Applicable

• Conditions: Stroke; Traumatic Brain Injuries; Acquired Brain Injuries; Cerebral Palsy; Multiple Sclerosis; Stroke - Haemorrhagic; Neurological - Other neurological disorders; Neurological - Multiple sclerosis; Neurological - Neurodegenerative diseases; Stroke - Ischaemic

• Registration Number: ACTRN12623001135606
• Lead Sponsor: A/Prof Ian Baguley

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-03
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

Clinical Group:
•Ability to understand verbal instructions in English
•Motor overactivity resulting from an UMN syndrome of greater than 3 months duration
•Predominately unilateral disability.
•Presence of active grip strength in the most affected upper limb (a minimum of 0.75kg of force)
* People who are receiving Botulinum Toxin-A injections as part of their spasticity management.

Control group
•Age 18+ years
•Ability to understand verbal instructions in English
•Available for two assessments

Exclusion Criteria

•Other causes of upper limb weakness including non-neurological pain, rheumatological conditions, lower motor neuron lesions, etc.
•Inadequate ability to understand and follow instructions, such as language barriers or inadequate voluntary motor control.
•People with spasticity who are not being offered OnabotulinumtoxinA injections as a clinical treatment.
* People with a known contraindication to OnabotulinumtoxinA e.g., Eaton-Lambert syndrome, pregnancy, hypersensitivity etc.

Control group
•Self-reported neurological impairment
•Self-reported acute or chronic arm injury or impairment

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maximum force generation data from Dynamic Computerised Dynamometry (DCD) for both the injected and non-injected upper limbs will be collected per published protocols and analysed offline,[ <=1 week pre-injection<br>4-6 weeks post Botulinum Toxin-A injection<br>for a maximum of 2 treatment cycles over a 6-12 month period.];Minimum force generation data from Dynamic Computerised Dynamometry (DCD) for both the injected and non-injected upper limbs will be collected per published protocols and analysed offline,[ <=1 week pre-injection<br>4-6 weeks post Botulinum Toxin-A injection<br>for a maximum of 2 treatment cycles over a 6-12 month period.];Contraction Velocity data from Dynamic Computerised Dynamometry (DCD) for both the injected and non-injected upper limbs will be collected per published protocols and analysed offline,[ <=1 week pre-injection<br>4-6 weeks post Botulinum Toxin-A injection<br>for a maximum of 2 treatment cycles over a 6-12 month period.]